Gilead Sciences (GILD) Misses Q2 EPS by 34c; Guides In-Line

Gilead Sciences (NASDAQ: GILD) reported Q2 EPS of $1.11, $0.34 worse than the analyst estimate of $1.45. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $5.31 billion.

GUIDANCE:

Gilead Sciences sees FY2020 EPS of $6.25-$7.65, versus the consensus of $6.71. Gilead Sciences sees FY2020 revenue of $23-25 billion, versus the consensus of $23.44 billion.

For earnings history and earnings-related data on Gilead Sciences (GILD) click here.

You May Also Be Interested In

• Academy Sports and Outdoor (ASO) Tops Q2 EPS by 22c, Offers Guidance
• Signet Jewelers (SIG) Tops Q2 EPS by 47c, Misses on Revenue; Offers FY27 Guidance
• Assembly Bio exercises U.S. profit-share option with Gilead for herpes program